{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:50:12Z","timestamp":1776772212719,"version":"3.51.2"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260715"],"award-info":[{"award-number":["82260715"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004607","name":"Guangxi Natural Science Foundation","doi-asserted-by":"publisher","award":["2025GXNSFBA069425"],"award-info":[{"award-number":["2025GXNSFBA069425"]}],"id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116290","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:33:16Z","timestamp":1769520796000},"page":"116290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["ResiDUBs: A deubiquitinating enzyme-based prognostic model identifies UBXN1 driving sorafenib resistance in liver cancer"],"prefix":"10.1016","volume":"173","author":[{"given":"Manqi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinrui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lichuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"74","key":"10.1016\/j.intimp.2026.116290_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"2024","author":"Bray","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2026.116290_bb0010","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41571-023-00825-3","article-title":"Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy","volume":"20","author":"Singal","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116290_bb0015","article-title":"Therapy of primary liver cancer","volume":"1","author":"Feng","year":"2020","journal-title":"Int. J. Hydrog Energ."},{"key":"10.1016\/j.intimp.2026.116290_bb0020","article-title":"Hepatocellular carcinoma: Updates on epidemiology, surveillance, diagnosis and treatment","author":"Hwang","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116290_bb0025","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.24.00857","article-title":"Liver transplantation for hepatocellular carcinoma: An expanding cornerstone of care in the era of immunotherapy","volume":"43","author":"Magyar","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116290_bb0030","first-page":"779","article-title":"Llovet, ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma","volume":"157","author":"Tabrizian","year":"2022","journal-title":"JAMA Surg."},{"key":"10.1016\/j.intimp.2026.116290_bb0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/jamasurg.2018.4334","article-title":"Risk factors, patterns, and outcomes of late recurrence after liver resection for hepatocellular carcinoma: a multicenter study from China","volume":"154","author":"Xu","year":"2019","journal-title":"JAMA Surg."},{"key":"10.1016\/j.intimp.2026.116290_bb0040","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"issue":"359","key":"10.1016\/j.intimp.2026.116290_bb0045","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"2008","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116290_bb0050","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1158\/1078-0432.CCR-18-1254","article-title":"The role of angiogenesis in hepatocellular carcinoma","volume":"25","author":"Morse","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116290_bb0055","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116290_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.20892\/j.issn.2095-3941.2022.0449","article-title":"Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies","volume":"20","author":"Yao","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.intimp.2026.116290_bb0065","article-title":"New insights on sorafenib resistance in liver cancer with correlation of individualized therapy, Biochimica et Biophysica acta (BBA) - reviews on","volume":"1874","author":"Cheng","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.intimp.2026.116290_bb0070","article-title":"Mechanisms of drug resistance in HCC","author":"Ladd","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2026.116290_bb0075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.canlet.2015.11.034","article-title":"MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS\/RAF\/ERK signaling pathways","volume":"371","author":"Xu","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116290_bb0080","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18533","article-title":"SOD1 inhibition enhances sorafenib efficacy in HBV-related hepatocellular carcinoma by modulating PI3K\/akt\/mTOR pathway and ROS-mediated cell death","volume":"28","author":"Lee","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.intimp.2026.116290_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0159-1","article-title":"Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors","volume":"50","author":"M\u00e9ndez-Blanco","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2026.116290_bb0090","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cac2.12414","article-title":"Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib","volume":"43","author":"Eun","year":"2023","journal-title":"Cancer Commun. (Lond.)"},{"key":"10.1016\/j.intimp.2026.116290_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2019.102610","article-title":"The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma","volume":"51","author":"Xia","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.intimp.2026.116290_bb0100","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1146\/annurev-biochem-061516-044916","article-title":"Mechanisms of deubiquitinase specificity and regulation","volume":"86","author":"Mevissen","year":"2017","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.intimp.2026.116290_bb0105","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","article-title":"Deubiquitinases in cancer","volume":"23","author":"Dewson","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2026.116290_bb0110","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s13402-024-00923-z","article-title":"Emerging roles of deubiquitinating enzymes in actin cytoskeleton and tumor metastasis","volume":"47","author":"Xue","year":"2024","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.intimp.2026.116290_bb0115","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.drudis.2022.06.009","article-title":"Deubiquitinating enzymes: promising targets for drug resistance","volume":"27","author":"Ge","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.intimp.2026.116290_bb0120","article-title":"The deubiquitinating enzyme USP8 promotes tyrosine kinase inhibitors resistance in chronic myeloid leukemia by stabilizing EIF2S1 protein","author":"Zhang","year":"2025","journal-title":"FEBS J."},{"key":"10.1016\/j.intimp.2026.116290_bb0125","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.7150\/ijbs.114686","article-title":"NDR1 enhances USP9X-mediated AR deubiquitination and promotes enzalutamide resistance in castration-resistant prostate cancer","volume":"21","author":"Zheng","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.intimp.2026.116290_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116372","article-title":"USP9X is a mechanosensitive deubiquitinase that controls tumor cell invasiveness and drug response through YAP stabilization","volume":"44","author":"Biber","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.116290_bb0135","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41419-025-08001-4","article-title":"The deubiquitylase OTUB1 drives gemcitabine resistance in pancreatic cancer by enhancing pyrimidine metabolism through modulating DHODH mRNA stability","volume":"16","author":"Zhang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.116290_bb0140","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41419-025-07969-3","article-title":"USP7 promotes temozolomide resistance by stabilizing MGMT in glioblastoma","volume":"16","author":"Li","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.116290_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217942","article-title":"OTUD3-mediated stabilization of SLC7A11 drives sunitinib resistance by suppressing ferroptosis in clear cell renal cell carcinoma","volume":"632","author":"Xu","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116290_bb0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41419-023-05777-1","article-title":"USP1 modulates hepatocellular carcinoma progression via the hippo\/TAZ axis","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.116290_bb0155","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41419-023-05747-7","article-title":"USP8 positively regulates hepatocellular carcinoma tumorigenesis and confers ferroptosis resistance through \u03b2-catenin stabilization","volume":"14","author":"Tang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.116290_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216439","article-title":"The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP","volume":"577","author":"Tian","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.intimp.2026.116290_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13062-024-00475-0","article-title":"OTUD5 promotes the growth of hepatocellular carcinoma by deubiquitinating and stabilizing SLC38A1","volume":"19","author":"Yang","year":"2024","journal-title":"Biol. Direct"},{"issue":"1","key":"10.1016\/j.intimp.2026.116290_bb0170","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41417-024-00869-2","article-title":"The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ","volume":"32","author":"Peng","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.intimp.2026.116290_bb0175","article-title":"USP22 promotes the proliferation and sorafenib resistance of hepatocellular carcinoma cells via its deubiquitinase activity","volume":"15","author":"Wang","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116290_bb0180","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41419-025-07772-0","article-title":"Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis","volume":"16","author":"Ye","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.116290_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114487","article-title":"Deubiquitylase OTUD3 regulates integrated stress response to suppress progression and sorafenib resistance of liver cancer","volume":"43","author":"Dai","year":"2024","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2026.116290_bb0190","article-title":"Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors","volume":"5","author":"Gy\u0151rffy","year":"2024","journal-title":"Int. J. Hydrog Energ."},{"issue":"51","key":"10.1016\/j.intimp.2026.116290_bb0195","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg3750","article-title":"Comprehensive analysis of spatial architecture in primary liver cancer","volume":"7","author":"Wu","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.intimp.2026.116290_bb0200","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-023-00882-y","article-title":"Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma","volume":"13","author":"Tan","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.intimp.2026.116290_bb0205","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat. Methods"},{"key":"10.1016\/j.intimp.2026.116290_bb0210","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26476","article-title":"Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data","volume":"6","author":"Racle","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.intimp.2026.116290_bb0215","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.intimp.2026.116290_bb0220","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht","year":"2016","journal-title":"Genome Biol."},{"key":"10.1016\/j.intimp.2026.116290_bb0225","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116290_bb0230","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med."},{"key":"10.1016\/j.intimp.2026.116290_bb0235","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2026.116290_bb0240","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2026.116290_bb0245","article-title":"Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116290_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.148526","article-title":"Value of CD8+ T cell-related genes and IL-6\/STAT3 signaling pathway in the prognosis of HCC and experimental investigation","volume":"332","author":"Wu","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.intimp.2026.116290_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1677089","article-title":"A lactylation-ferroptosis cross-talk gene signature predicts hepatocellular carcinoma prognosis and reveals STMN1\/PRDX1 as therapeutic targets","volume":"16","author":"Meng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116290_bb0260","doi-asserted-by":"crossref","first-page":"14999","DOI":"10.18632\/aging.203061","article-title":"Inhibiting USP8 overcomes hepatocellular carcinoma resistance via suppressing receptor tyrosine kinases","volume":"13","author":"Zhu","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.intimp.2026.116290_bb0265","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s12916-023-03066-4","article-title":"ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization","volume":"21","author":"Lu","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2026.116290_bb0270","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.15252\/embj.201695669","article-title":"USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling","volume":"36","author":"Luo","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2026.116290_bb0275","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1660034","article-title":"FBXO2 promotes hepatocellular carcinoma progression and sorafenib resistance by targeting USP49 for proteasomal degradation","volume":"16","author":"Hang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116290_bb0280","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116290_bb0285","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41419-020-02998-6","article-title":"PI3K\/AKT pathway as a key link modulates the multidrug resistance of cancers","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.116290_bb0290","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.intimp.2026.116290_bb0295","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-020-01629-4","article-title":"Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma","volume":"39","author":"Feng","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116290_bb0300","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2026.116290_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107753","article-title":"Tumor microenvironment as a therapeutic target in cancer","volume":"221","author":"Xiao","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2026.116290_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100797","article-title":"Impact of cancer metabolism on therapy resistance \u2013 clinical implications","volume":"59","author":"Gon\u00e7alves","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.intimp.2026.116290_bb0315","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41416-019-0482-x","article-title":"M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma","volume":"121","author":"Dong","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.intimp.2026.116290_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112807","article-title":"M2 macrophage exosomes promote resistance to sorafenib in hepatocellular carcinoma cells via miR-200c-3p","volume":"139","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116290_bb0325","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13046-018-0934-9","article-title":"Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity","volume":"37","author":"Qin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116290_bb0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7150\/thno.36930","article-title":"Macrophage MSR1 promotes BMSC osteogenic differentiation and M2-like polarization by activating PI3K\/AKT\/GSK3\u03b2\/\u03b2-catenin pathway","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2026.116290_bb0335","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/15548627.2021.1922982","article-title":"VCP\/p97 cofactor UBXN1\/SAKS1 regulates mitophagy by modulating MFN2 removal from mitochondria","volume":"18","author":"Mengus","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.intimp.2026.116290_bb0340","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s44319-023-00027-z","article-title":"UBXN1 maintains ER proteostasis and represses UPR activation by modulating translation","volume":"25","author":"Ahlstedt","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.intimp.2026.116290_bb0345","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s11427-023-2429-5","article-title":"SUB1 promotes colorectal cancer metastasis by activating NF-\u03baB signaling via UBR5-mediated ubiquitination of UBXN1","volume":"67","author":"Wang","year":"2024","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.intimp.2026.116290_bb0350","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01124-z","article-title":"YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-\u03baB and promote the malignant progression of glioma","volume":"14","author":"Chai","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116290_bb0355","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12967-024-05208-5","article-title":"UBXN1 promotes liver tumorigenesis by regulating mitochondrial homeostasis","volume":"22","author":"Jiao","year":"2024","journal-title":"J. Transl. Med."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926001335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:11:47Z","timestamp":1776769907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":71,"alternative-id":["S1567576926001335"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116290","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ResiDUBs: A deubiquitinating enzyme-based prognostic model identifies UBXN1 driving sorafenib resistance in liver cancer","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116290"}}